{"title":"Cardioprotective benefits of metabolic surgery and GLP-1 receptor agonist-based therapies.","authors":"Arianne Morissette, Erin E Mulvihill","doi":"10.1016/j.tem.2024.07.012","DOIUrl":null,"url":null,"abstract":"<p><p>Individuals with excessive adipose tissue and type 2 diabetes mellitus (T2DM) face a heightened risk of cardiovascular morbidity and mortality. Metabolic surgery is an effective therapy for people with severe obesity to achieve significant weight loss. Additionally, metabolic surgery improves blood glucose levels and can lead to T2DM remission, reducing major adverse cardiovascular outcomes (MACE). Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1RAs) are a class of medication that effectively reduce body weight and MACE in patients with T2DM. This review explores the potential mechanisms underlying the cardioprotective benefits of metabolic surgery and GLP-1RA-based therapies and discusses recent evidence and emerging therapies in this dynamic area of research.</p>","PeriodicalId":54415,"journal":{"name":"Trends in Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":11.4000,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in Endocrinology and Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.tem.2024.07.012","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Individuals with excessive adipose tissue and type 2 diabetes mellitus (T2DM) face a heightened risk of cardiovascular morbidity and mortality. Metabolic surgery is an effective therapy for people with severe obesity to achieve significant weight loss. Additionally, metabolic surgery improves blood glucose levels and can lead to T2DM remission, reducing major adverse cardiovascular outcomes (MACE). Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1RAs) are a class of medication that effectively reduce body weight and MACE in patients with T2DM. This review explores the potential mechanisms underlying the cardioprotective benefits of metabolic surgery and GLP-1RA-based therapies and discusses recent evidence and emerging therapies in this dynamic area of research.
期刊介绍：
Trends in Endocrinology and Metabolism (TEM) stands as a premier Reviews journal in the realms of metabolism and endocrinology. Our commitment is reflected in the publication of refined, concise, and highly impactful articles that delve into cutting-edge topics, encompassing basic, translational, and clinical aspects. From state-of-the-art treatments for endocrine diseases to groundbreaking developments in molecular biology, TEM provides comprehensive coverage.
Explore recent advancements in diabetes, endocrine diseases, obesity, neuroendocrinology, immunometabolism, molecular and cellular biology, and a myriad of other areas through our journal.
TEM serves as an invaluable resource for researchers, clinicians, lecturers, teachers, and students. Each monthly issue is anchored by Reviews and Opinion articles, with Reviews meticulously chronicling recent and significant developments, often contributed by leading researchers in specific fields. Opinion articles foster debate and hypotheses. Our shorter pieces include Science & Society, shedding light on issues at the intersection of science, society, and policy; Spotlights, which focus on exciting recent developments in the literature, and single-point hypotheses as Forum articles. We wholeheartedly welcome and encourage responses to previously published TEM content in the form of Letters.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
